4DMedical Ltd
OTC:FDMDF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
4
|
4DMedical Ltd
OTC:FDMDF
|
AU |
|
P
|
PharmaRoth Labs Inc
OTC:ROTH
|
US |
|
L
|
Lear Corp
LSE:0JTQ
|
US |
|
Shanghai Sinyang Semiconductor Materials Co Ltd
SZSE:300236
|
CN |
|
E
|
Endava PLC
F:2Y5
|
UK |
|
H
|
Hydration Pharmaceuticals Co Ltd
ASX:HPC
|
AU |
|
Poste Italiane SpA
OTC:PITAF
|
IT |
|
J
|
JSW Infrastructure Ltd
BSE:543994
|
IN |
|
S
|
Sixt SE
XHAM:SIX3
|
DE |
|
AML3D Ltd
F:4YP
|
AU |
|
S
|
Sunway Real Estate Investment Trust
KLSE:SUNWAY
|
MY |
|
Mitchell Services Ltd
ASX:MSV
|
AU |
|
Hankyu Hanshin Holdings Inc
F:HKY
|
JP |
|
C
|
Computer Forms (Malaysia) Bhd
KLSE:CFM
|
MY |
|
KDA Group Inc
OTC:KDAGF
|
CA |
|
Premier Miton Group PLC
LSE:PMI
|
UK |
|
Dino Polska SA
OTC:DNOPF
|
PL |
|
Knowledge Marine & Engineering Works Ltd
NSE:KMEW
|
IN |
|
Mira Pharmaceuticals Inc
F:K6S
|
US |
|
N
|
Noratis AG
SWB:NUVA
|
DE |
|
A
|
AuGroup SHENZHEN Cross Border Business Co Ltd
HKEX:2519
|
CN |
|
Synlait Milk Ltd
NZX:SML
|
NZ |
|
C
|
CMS Energy Corp
DUS:CSG
|
US |
|
Kelt Exploration Ltd
TSX:KEL
|
CA |
4DMedical Ltd
4DMedical Ltd makes software that helps doctors see how the lungs are working, not just what they look like. Its main products analyze chest scans from standard medical imaging systems and turn them into functional pictures of airflow and ventilation. That gives clinicians a clearer view of respiratory disease without requiring a new scanner. The company sells its software and analysis services to hospitals, radiology groups, and healthcare providers, and it also works with pharmaceutical companies and research groups that need lung-imaging data for trials and studies. It makes money through software licenses, subscriptions, and service contracts, plus project-based work tied to clinical research and imaging analysis. What makes 4DMedical different is that it sits between imaging equipment and patient care: it does not build the scanner, it helps existing scanners do more. That means its business depends on getting its software adopted by medical institutions and by companies that need better lung-function measurements for diagnosis, monitoring, and drug development.
4DMedical Ltd makes software that helps doctors see how the lungs are working, not just what they look like. Its main products analyze chest scans from standard medical imaging systems and turn them into functional pictures of airflow and ventilation. That gives clinicians a clearer view of respiratory disease without requiring a new scanner.
The company sells its software and analysis services to hospitals, radiology groups, and healthcare providers, and it also works with pharmaceutical companies and research groups that need lung-imaging data for trials and studies. It makes money through software licenses, subscriptions, and service contracts, plus project-based work tied to clinical research and imaging analysis.
What makes 4DMedical different is that it sits between imaging equipment and patient care: it does not build the scanner, it helps existing scanners do more. That means its business depends on getting its software adopted by medical institutions and by companies that need better lung-function measurements for diagnosis, monitoring, and drug development.
Revenue Growth: 4DMedical reported a 16.5% half-to-half revenue increase, with a $6 million recurring revenue run rate, though recent contract wins are not yet fully reflected in these numbers.
Cost Management: Operating expenditure dropped by 11% half-on-half, and management says the company is well past its peak spending.
Capital Raising: The company is completing a $12.5 million placement and SPP, structured to potentially bring in $30 million in total, aimed at funding the business through to breakeven.
Philips Partnership: The Philips reseller agreement is expected to bring contracts and meaningful revenue before June 30, with Philips' 250 salespeople now selling 4DMedical products.
Product Momentum: Recent FDA approval and $650 Medicare reimbursement for IQ-UIP, as well as growth in scan volumes, sites, and average price per scan, are driving momentum.
Australia and U.S. Trends: U.S. revenue is rising significantly; Australian revenue appeared to drop due to a legacy contract rolling off, but underlying business there has grown by 40% recently.
VQ Product Launch: The upcoming VQ product is positioned as a superior, logistically easier alternative to nuclear medicine VQ scans, targeting a $1 billion U.S. market.